Discover
ARQT
Arcutis Biotherapeutics, Inc.
26.23
22 x 26.23
1 x 26.25
bid
ask
+
0.31
1.20%
3 @ 04:00 PM
26.40 +0.17 (0.65%)
| Ytd | -9.68% | |
| 1y | 84.85% |
25.91
day range
26.82
14.08
52 week range
31.77
| Open | 26.24 | Prev Close | 25.92 | Low | 25.91 | High | 26.82 | Mkt Cap | 3.28B |
| Vol | 0.00 | Avg Vol | 1.77M | EPS | 0.21 | P/E | 124.90 | Forward P/E | 19.89 |
| Beta | 1.53 | Short Ratio | 7.34 | Inst. Own | 109.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 25.96 | 200-d Avg | 25.46 | 1yr Est | 36.88 |
| Income Statement | |||
| Total Revenue | 129.86M | ||
| Revenues (USD) | 129.86M | ||
| Cost of Revenue | 10.94M | ||
| Gross Profit | 118.92M | ||
| Operating Expenses | 102.49M | ||
| Research and Development Expense | 20.36M | ||
| Selling, General and Administrative Expense | 82.14M | ||
| Operating Income | 16.43M | ||
| Interest Expense | 3.41M | ||
| Income Tax Expense | 136.00K | ||
| Net Income | 15.01M | ||
| Net Income Common Stock | 15.01M | ||
| Net Income Common Stock (USD) | 15.01M | ||
| Consolidated Income | 15.01M | ||
| Earnings per Basic Share | 0.11 | ||
| Earnings per Basic Share (USD) | 0.11 | ||
| Earnings per Diluted Share | 0.11 | ||
| Earning Before Interest & Taxes (EBIT) | 18.55M | ||
| Earning Before Interest & Taxes (USD) | 18.55M | ||
| Weighted Average Shares | 130.52M | ||
| Weighted Average Shares Diluted | 135.90M | ||
| Balance Sheet | |||
| Cash and Equivalents | 34.43M | ||
| Cash and Equivalents (USD) | 34.43M | ||
| Investments | 204.43M | ||
| Investments Current | 204.43M | ||
| Trade and Non-Trade Receivables | 155.16M | ||
| Current Assets | 467.67M | ||
| Property, Plant & Equipment Net | 5.13M | ||
| Total Assets | 488.54M | ||
| Debt Current | 6.95M | ||
| Total Debt | 114.14M | ||
| Current Liabilities | 160.34M | ||
| Debt Non-Current | 107.19M | ||
| Total Liabilities | 267.96M | ||
| Accumulated Retained Earnings (Deficit) | -1.13B | ||
| Accumulated Other Comprehensive Income | -656.00K | ||
| Shareholders Equity | 220.58M | ||
| Shareholders Equity (USD) | 220.58M | ||
| Assets Non-Current | 20.87M | ||
| Total Debt (USD) | 114.14M | ||
| Goodwill and Intangible Assets | 13.69M | ||
| Inventory | 38.88M | ||
| Liabilities Non-Current | 107.62M | ||
| Trade and Non-Trade Payables | 6.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 563.00K | ||
| Net Cash Flow from Financing | 1.99M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -641.00K | ||
| Capital Expenditure | -158.00K | ||
| Issuance (Purchase) of Equity Shares | 2.99M | ||
| Issuance (Repayment) of Debt Securities | -1000.00K | ||
| Net Cash Flow from Investing | -15.22M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -15.07M | ||
| Net Cash Flow from Operations | 12.64M | ||
| Effect of Exchange Rate Changes on Cash | -46.00K | ||
| Share Based Compensation | 12.76M | ||